JAMA Internal Medicine
EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, FEBRUARY 24, 2021
Media advisory: The full study and editor’s note are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2021.0366?guestAccessKey=3e87dda5-1626-4a94-8716-5b73e3534d44&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=022421
What The Study Did: Researchers use a large set of clinical laboratory data linked to other clinical information such as claims to investigate the relationship between SARS-CoV-2 antibody status and subsequent nucleic acid amplification test (NAAT) results in an effort to understand how serostatus may predict risk of reinfection.
Authors: Lynne T. Penberthy, M.D., M.P.H., of the National Cancer Institute at the National Institutes of Health in Rockville, Maryland, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.